|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.37 EUR | -0.10% |
|
+9.20% | +88.31% |
| 12-12 | Bayer Wins EU Panel's Recommendation for Eye Disease Drug's New Indication | MT |
| 12-12 | BAYER AG : Berenberg reiterates its Neutral rating | ZD |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 48.25B | -5.48% | 11.66% | 15.32% | -2.25% | 3.2x | ||
| 45.04B | 23.51% | 31.78% | 84.84% | 14.84% | 1.88x | ||
| 88.82B | 15.84% | 29.8% | 34.23% | 13.95% | 0.41x | ||
| 56.33B | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
| 66.76B | 13.68% | 34.42% | 43.45% | 15.69% | 0.74x | ||
| 54.07B | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
| 50.32B | 23.73% | 38.74% | 34.74% | 15.58% | 0.85x | ||
| 64.17B | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
| 40.31B | 34.78% | 44.19% | 80.78% | 25.88% | 0.52x | ||
| 33.42B | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
| 28.75B | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
| 63.63B | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
| 42.53B | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
| 11.02B | -4.86% | 6.31% | 0.65% | 0.49% | -6.77x | ||
| 48.3B | -18.53% | 10.77% | 10.23% | -9.53% | 6.49x | ||
| 39.28B | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
| 7.45B | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
| 3.83B | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
| 2.25B | -12.37% | -7.87% | - | -6.89% | 1.85x | ||
| Average | 41.82B | 11.69% | 28.83% | 53.73% | 9.87% | 0.87x | |
| Weighted average by Cap. | 51.44B | 15.98% | 32.65% | 72.56% | 13% | 1.16x |
- Stock Market
- Equities
- BAYN Stock
- Sector Bayer AG
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















